Cancer Vaccines
New research on cancer vaccines from Osaka University summarized
Published in Clinical Trials Week, December 3rd, 2007
According to recent research from Suita, Japan, "The wild-type Wilms tumor gene, WT1, is overexpressed in myelodysplastic syndrome (MDS) as well as acute myeloid leukemia. In a phase I clinical trial of biweekly vaccination with HLA-A*2402-restricted WT1 peptide for these malignancies, 2 patients with MDS developed severe leukocytopenia in association with a reduction in leukemic blast cells and levels of WT1 messenger RNA (mRNA) after only a single vaccination with 0.3 mg of WT1 peptide."
"These results indicated that the WT1-specific cytotoxic T-lymphocytes (CTLs) elicited by WT1 vaccination eradicated the WT1-expressing transformed stem or progenitor cells and that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2007-12-03)
More Articles from Clinical Trials Week
- Clinical Trial Research
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study - Combination Therapy
LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study - Gene Therapy
Ability of Neurologix's Gene Transfer Therapy to Quiet Abnormal Brain Activity in Parkinson's Disease Patients Reported in PNAS - Myeloma
The International Myeloma Foundation Says REVLIMID(R) Extends Survival with Positive Implications for a Wide Range of Blood Cancers - Allergies
New allergies study findings recently were published by S. Wenzel and co-researchers - Bladder Cancer
Researchers at University of Toronto target bladder cancer - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
